HC Wainwright Brokers Decrease Earnings Estimates for XBIO

Xenetic Biosciences Inc (NASDAQ:XBIO) – Equities researchers at HC Wainwright dropped their FY2025 earnings estimates for Xenetic Biosciences in a research note issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($3.24) for the year, down from their prior forecast of ($0.66). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2026 earnings at ($0.45) EPS, FY2027 earnings at ($0.54) EPS and FY2028 earnings at ($0.48) EPS.

Xenetic Biosciences Stock Performance

NASDAQ XBIO opened at $3.38 on Monday. Xenetic Biosciences has a 52 week low of $2.78 and a 52 week high of $5.20. The stock’s 50 day moving average price is $3.95 and its two-hundred day moving average price is $3.99. The stock has a market capitalization of $5.21 million, a price-to-earnings ratio of -1.27 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). The firm had revenue of $0.65 million during the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation acquired a new position in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned about 0.71% of Xenetic Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.